Autoimmune haemolytic anaemia treated by therapeutic plasma exchange and retuximab: A case report
Autoimmune hemolytic anaemia
Autoimmune haemolytic anaemia (AIHA) is an uncommon disorder characterized by shortened red blood cell (RBC) survival and the presence of autoantibodies directed against autologous RBCs. It presents with anaemia, jaundice, and splenomegaly with reticulocytosis, unconjugated hyperbilirubinaemia, and direct antiglobulin test (DAT) positivity.' AIHA has an estimated incidence of 1—3 cases per 100,000 subjects per year, a prevalence of 17:100,000 and a mortality rate of 11%.' AIHA is classified as warm AIHA (75.0% of all AIHA cases), cold AIHA (about 15.0%), and mixed type AIHA (less than 5.0%), based on the thermal range of autoantibodies involved in the pathogenesis.6 It can be idiopathic (50.0%) or secondary to lymphoproliferative syndromes (20.0%), autoimmune diseases (20.0%), infections, tumors and drugs.’ The laboratory diagnosis of AIHA depends on the result of direct antiglobulin test (DAT) which shows positivity with anti-IgG (usually in warm AIHA) and/or anti-C3d (usually in cold AIHA) antisera, and also the presence of laboratory findings supporting hemolysis such as increase of serum lactate dehydrogenase (LDH), reticulocytosis and spherocytosis in peripheral blood smears.‘ The treatment of AIHA is still not evidence-based. The first-line therapy for warm AIHA is corticosteroids, which are effective in 70.0-85.0% of patients and should be slowly tapered over a time period of 6-12 months. For refractory/relapsed cases, the current sequence of second-line therapy is splenectomy (effective approx. in 2 out of 3 cases but with a presumed cure rate of up to 20.0%), rituximab (effective in approx. 80.0-90.0% of cases), and thereafter any of the immunosuppressive drugs (azathioprine, cyclophosphamide, cyclosporin, mycophenolate mofetil). Additional therapies are intravenous immunoglobulins, danazol, plasma-exchange, and alemtuzumab and high-dose cyclophosphamide as last resort option.’ Most of the immunosuppressive drugs have many deleterious side-effects and the onset of action is slow. Splenectomy carries the risk of an overwhelming post splenectomy sepsis.‘ Rituximab (so called “medical splenectomy”) is an effective second-line therapy, can work quickly with lasting effects, providing high initial response rates up to 87.0% and prolonged disease free survivals of 56.0% up to 2 years with reduced adverse reactions.‘ ' For warm AIHA, rituximab therapy is considered as a second line option as monotherapy or combined therapy. It can also be used as a first line therapy in combination with steroids for newly diagnosed patients. ' Another option, with less supportive
evidence in the literature, is the use of therapeutic plasma exchange (TPE) to quickly reduce the pahologic antibody titer in patients with an overwhelming hemolysis. 2 TPE has been performed in a relatively small
number of severely affected warm AIHA patients in whom the anemia could not be stabilized with steroids
and transfusion therapy alone, as a temporizing measure which seemed to stabilize the disease and increase the efficiency of blood transfusions.4 Current indication categories endorsed by the American Association of Blood Banks (AABB) and the American Society for Apheresis, TPE for AIHA is considered as acategory III indication, i.e. an application representing “heroic or last-ditch efforts on behalf of a patient”." Decision to transfuse RBC in AIHA should be based on the clinical condition of the patient. No critical patient should be denied blood transfusion due to serological incompatibility and “the least incompatible” RBC should be transfused in this situation.4 ”' Severe AIHA cases sometimes misdiagnosed or lately diagnosed. Early diagnosis and appropriate emergency interventions can save the life of these patients. In this case, we demonstrate the concomitant use of TPE and rituximab in the treatment of life-threatening warm AIHA.
Bangladesh Med Res Counc Bull 2019; 45: 126-128
174 ONLINE VIEW
Copyright (c) 2019 Bangladesh Medical Research Council
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms.
Authors retain copyright and grant the journal right of first publication.
Articles in the Bangladesh Medical Research Council Bulletin are licensed under a Creative Commons Attribution 4.0 International License (CC-BY) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).